Coeptis Therapeutics, Inc. (COEP)

NASDAQ: COEP · IEX Real-Time Price · USD

0.286

-0.012 (-3.99%)

At close: Jul 19, 2024, 4:00 PM

0.294

+0.008 (2.87%)

Pre-market: Jul 22, 2024, 7:01 AM EDT

Coeptis Therapeutics Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year Ending	TTM	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019
Revenue	0	0	0	0.08	0.03	0
Revenue Growth (YoY)	-	-	-	143.82%	-	-
Cost of Revenue	0	0	0	0	0.96	0
Gross Profit	0	0	0	0.08	-0.93	0
Selling, General & Admin	10.29	14.82	34.18	14.12	5.78	0
Research & Development	7.33	6.67	0.02	0	0	0
Other Operating Expenses	0.25	0	0	0	0	0
Operating Expenses	17.87	21.49	34.2	14.12	5.78	0
Operating Income	-17.87	-21.49	-34.2	-14.05	-6.71	-0
Interest Expense / Income	0.28	0.11	0.22	0.19	0.15	0
Other Expense / Income	-1.84	-0.33	3.16	-0.78	2.29	-
Pretax Income	-16.31	-21.27	-37.57	-13.45	-9.16	-0
Net Income	-16.31	-21.27	-37.57	-13.45	-9.16	-0
Shares Outstanding (Basic)	36	26	14	11	18	2
Shares Outstanding (Diluted)	36	26	14	11	18	2
Shares Change	76.98%	79.70%	30.98%	-39.66%	944.93%	-
EPS (Basic)	-0.54	-0.83	-2.63	-1.23	-0.51	-
EPS (Diluted)	-0.54	-0.83	-2.63	-1.23	-0.51	-
Free Cash Flow	-7.46	-7.24	-3.88	-4.49	-3.14	-0
Free Cash Flow Per Share	-0.21	-0.28	-0.27	-0.41	-0.17	-0.00
Gross Margin	-	-	-	100.00%	-3034.54%	-
Operating Margin	-	-	-	-18727.91%	-21823.77%	-
Profit Margin	-	-	-	-17932.37%	-29765.89%	-
Free Cash Flow Margin	-	-	-	-5985.92%	-10195.12%	-
EBITDA	-15.03	-20.16	-36.35	-12.81	-8.68	-0
EBITDA Margin	-	-	-	-17086.31%	-28232.72%	-
Depreciation & Amortization	1	1	1	0.45	0.32	0
EBIT	-16.03	-21.16	-37.36	-13.26	-9.01	-0
EBIT Margin	-	-	-	-17682.86%	-29284.14%	-

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).